Navigation Links
Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
Date:10/5/2007

RIDGEFIELD, Conn., Oct. 5 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted full (traditional) approval of Aptivus(R) (tipranavir) capsules. The FDA granted accelerated approval to APTIVUS in June 2005; accelerated approval is a regulatory process that expedites the approval of therapies for serious or life-threatening illnesses. The full approval of APTIVUS is based largely on 48-week analyses of the Phase 3 pivotal clinical studies known as the RESIST (Randomized Evaluation of Strategic Intervention in Multi-Drug ReSistant Patients with Tipranavir) trials. These trials comprise one of the largest study programs conducted in treatment-experienced HIV patients.

"Data show that APTIVUS/r may provide treatment-experienced HIV patients with an effective treatment option through nearly one year of therapy. Furthermore, longer-term safety data are now available for physician and patient consideration," said Dr. Daniel Kuritzkes, associate professor of medicine, Harvard Medical School; director of AIDS research, Brigham and Women's Hospital, Boston, MA.

APTIVUS, a protease inhibitor, co-administered with 200 mg of ritonavir (APTIVUS/r), is indicated for combination antiretroviral treatment of HIV-1 infected adult patients who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor.

This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of APTIVUS/r of 48 weeks duration. Both studies were conducted in clinically advanced, 3-class antiretroviral (NRTI, NNRTI, PI) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

The following points should be considered when initiating therapy with APTIVUS/r:

-- The use of APTIVUS/r in treatment-nave patients is not recommended.

-- The use of other active agents with APTIVUS/r is as
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
2. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
3. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...EO, Calif., Sept. 4 /- BioF... that the pivotal clinical study of,Polidocanol, c...Chemische,Fabrik KREUSSLER & Co. GmbH (Kreussler),...as been submitted to FDA as part of a New Drug App...study, named the EASI (Efficacy and safety of,Aeth...
(Date:9/4/2008)...a Published in ,The Lancet, and Presented at ESC C...esults from a new international,study, the GISSI H...ose of,omega-3 acid ethyl esters reduced all cause...lar reasons in patients with chronic heart,failure...ne version of ,The,Lancet, and were presented at t...
(Date:9/4/2008)...HAM, Ala., Sept. 4 /- Southern Resear...titutes of Health (NIH) has selected,the organizat...ibraries,Probe Production Center Network (MLPCN). ...s part of the Molecular Libraries Program which is...fic knowledge of the human,genome and validate fut...
(Date:9/4/2008)... Switzerland, September 4 /- Axentis ... to assess the safety and tolerability,of a new th...pulmonary,infection in cystic fibrosis patients. T...ic agent to be delivered directly to the site of,i...the effects of two,different doses of the new drug...
Breaking Medicine Technology:338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4UK government has reneged on pledge for flexible working in NHS 5992 1UK government has reneged on pledge for flexible working in NHS 5992 2Researchers successfully simulate photosynthesis and design a better leaf 1169 1Researchers successfully simulate photosynthesis and design a better leaf 1169 2Researchers successfully simulate photosynthesis and design a better leaf 1169 3Abnormal immune cells may cause unprovoked anaphylaxis 5990 1Abnormal immune cells may cause unprovoked anaphylaxis 5990 2Abnormal immune cells may cause unprovoked anaphylaxis 5990 3Research highlights important indicators of early stage ovarian cancer 5988 1
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...ldrens Hospital Medical Center study shows that a ...obese teens when run by pediatricians in the offi...ting of the Pediatric Academic Societies in Toront...s who completed the six-month study lost weight, a...
...the controversial icon of the right is no more . ...jority and used it to mold the religious right int...ing found unconscious in his office at Liberty Uni...died suddenly of what his doctor suspects was the ...
...s bad tidings for those heavy-handed on multivitam...s National Cancer Institute , reveals that those w...k, can in fact increase their risk of contracting ...r. The researchers who published their work in ...
... the number of urban parks and street trees in our...mperature rise, a new study by researchers from t...ng to the team, a mere 10 percent increase in the ...ntres would reduce urban surface temperatures by a...
Other Medicine News:Health News:Low-Carb Diet Effective for Teens Trying to Lose Weight 2Health News:Extremist Christian Preacher Dies of Heart Problems 2Health News:Being Overzealous With Multivitamins May Lead To Prostate Cancer 2Health News:Modest Increase in Urban Parks Could Equalize Global Warming Until 2080s 2
PacePath is a comprehensive anatomic pathology software system that is the culmination of more than five years of development and testing by leading industry experts.
Velocity works cooperatively with LabSofts LabNet LIS, allowing the convenience of 24-hour access to information from satellite lab locations, hospitals, physician offices and even homes.
...eld (130" x 85") allows the surgeon to view the pa...hile remaining in the sterile field. , ,Electroca...ling cords while maintaining longer cord length st...large particle screen accommodates the larger inci...
The Bohn™ Extremity Drape is economically sound - this single extremity drape replaces two large antimicrobial impregnated "Vi-Drapes" ...the traditional "shower curtain"...and your current "ex
Medicine Products: